Harold J. Burstein, MD, PhD, and Lisa A. Carey, MD, on Innovations in Triple-Negative Breast Cancer

2014 San Antonio Breast Cancer Symposium

Harold J. Burstein, MD, PhD, of the Dana-Farber Cancer Institute and Lisa Carey, MD, of the UNC Lineberger Comprehensive Cancer Center, discuss:

The TNT trial comparing docetaxel to carboplatin
The CALGB trial on response rates after neoadjuvant chemo with or without carboplatin or bevacizumab
Pembrolizumab in a phase Ib study

Harold J. Burstein, MD, PhD, and Lisa A. Carey, MD, on Innovations in Triple-Negative Breast Cancer

Related Videos

Charles E. Geyer, Jr, MD, FACP, on the SOFT Trial

Hope S. Rugo, MD, on the Phase II FIRST Study

Jame Abraham, MD, FACP, on Immunotherapy in Triple-Negative Breast Cancer

Ann H. Partridge, MD, MPH, on Patient-Reported Outcomes From the SOFT Trial

Gunter von Minckwitz, MD, on the Phase III ICE Trial

Oxybutynin May Improve ADT-Induced Hot Flashes in Patients With Prostate Cancer

Determining the Optimal Duration of Androgen-Deprivation Therapy Added to Definitive Radiotherapy in Localized Prostate Cancer

Induction Nivolumab Before CRT in High-Risk HPV-Driven OPC

Neoadjuvant Taxane Plus Trastuzumab and Pertuzumab With or Without Carboplatin in HER2-Positive Breast Cancer

Nonmetastatic Breast Cancer Treatment Strategies After Denosumab Discontinuation in Patients Treated With Aromatase Inhibitors